Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la ...

www.speakup-sanofi.com Tel.: 00 800 111 3819 Tel. 00 800 141 0213 Infolinie w języku polskim ...

Niniejszym informujemy, że zgodnie z wymogami Ustawy z dnia 14 czerwca 2024 r. o ochronie sygnalistów, firma Sanofi Sp. z o.o. wdrożyła lokalną Procedurę Zgłoszeń Wewnętrznych i Podejmowania Działań ...

Jean-Paul Kress to join Sanofi's Board of Directors Paris, . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, ...

Le sepsis est une condition potentiellement mortelle qui se produit lorsque le système immunitaire de l’organisme réagit de manière excessive à une infection. S’il n’est pas détecté et traité ...

Sepsis is a life-threatening condition that happens when the body’s immune system has an extreme response to an infection.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the ...

Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...

Many symptoms of MS are visible to the outside world, such as movement or speech problems, but there are also invisible symptoms (unseen by others) that significantly impact the lives of those living ...